BackKeymed Biosciences Overview

Keymed Biosciences EBIT

Latest ebit for 2162.HK: $-980M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$142.74M
↓ 6.26% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$980.79M
↑ 23.24% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Keymed Biosciences (2162.HK) FAQ

The latest EBIT for 2162.HK is $-980M as of June 2026. That compares with $-1.3B in the prior-year period — up 23.2% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Keymed Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, 2162.HK's EBIT moved from $-1.3B to $-980M — a 23.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Keymed Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, 2162.HK currently prints $-980M for EBIT, while the sector average sits near $1.9T. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Keymed Biosciences's growth, margins, and balance sheet.

A EBIT figure of $-980M for 2162.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting 2162.HK's EBIT ($-980M), review year-over-year change from $-1.3B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers